By binding to alpha-4 integrin receptor sites, Tysabri selectively blocks leukocyte adhesion to blood vessel walls and subsequent migration of these immune cells to sites of chronic inflammation, where they can exacerbate the inflammatory process. Leukocytes are believed to mediate the damage to the protective myelin sheath of nerve cells seen in multiple sclerosis.
According to information released by Biogen Idec, as of August 4, 2011 there have been 150 confirmed cases of progressive multifocal leukoencephalopathy (PML, a viral infection of the brain that usually leads to death or severe disability) among people who have used Tysabri® (natalizumab, Biogen Idec and Elan Pharmaceuticals) after it became available for prescription in July 2006. Of the cases, 85 occurred in Europe, 58 occurred in the United States, and 7 occurred in the rest of the world. As of June 30, 2011, approximately 88,100 people worldwide have used Tysabri since it was marketed.
David1949 wrote:I've been one who thinks that Daflon might offer some help for CCSVI. But I'm not sure it's a good idea to buy the stuff over the internet and try it out on yourself. I hope you will be very careful about this or maybe not do it at all until more is known about it. At least we should find out how Ginger is doing on it.
I know all of us want to be free of this MS monster, but I don't think we should throw caution to the wind.
Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease.
Service de Rhumatologie, Hôpital Bichat, Paris, France.
Daflon 500 mg is a new flavonoid vasoprotector venotonic agent whose active principle is micronized and contains 90% diosmin and 10% flavonoids expressed as hesperidin. In animal studies, the safety of Daflon 500 mg is shown by an LD50 (lethal dose 50) of more than 3 g/kg, ie, 180 times the daily therapeutic dose, as well as by the absence of any toxic effect after repeated oral dosing for thirteen and twenty-six weeks, using a dose representing 35 times the daily dosage, in the rate and primate. Daflon 500 mg has no mutagenic action nor any significant effect on reproductive function. Gastrointestinal tolerance is good when administered orally in the rat. Transplacental passage and passage into breast milk are minimal. In the rat, 0.003% of the administered dose has been found in each fetus and 1% in breast milk. Clinical trials fulfill international scientific requirements and have collected more than 2850 patients treated with Daflon 500 mg at the dosage of two tablets per day for six weeks to one year. The proportion of patients with side effects (10% of those treated), essentially of a gastrointestinal or autonomic nature and leading to a rate of only 1.1% trial dropouts, is less than described in 225 patients given a placebo (13.9%) in controlled trials. Satisfactory clinical acceptability already confirmed in the short term was equally found in long-term treatment. Hemodynamic parameters (systolic and diastolic blood pressure) as well as laboratory parameters (hematology, liver and renal function, metabolic) were uninfluenced even by prolonged treatment for one year at the dosage of two tablets per day.
Ruthless67 wrote:Hi All,
It's been 3 days since I started the Diosmin and like all things MS it's sometimes hard to tell what is going on. I have two vericose vein areas on my left calf, and they don't appear to have changed any. My legs still feel heavy and "numbish" like usual, but my feet are warmer, and sometimes they and my numb hands feel alittle tingly. So I'll continue with the 30 day supply.
Users browsing this forum: No registered users